From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
LysRs-IN-2 is a lysyl-tRNAsynthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNAsynthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNAsynthetase (CpKRS), respectively .
Histidyl-tRNAsynthetase, human is responsible for the synthesis of histidyl-transfer RNA, which is essential for the incorporation of histidine into proteins. Histidyl-tRNAsynthetase has been found to act as a particularly important antigen in autoimmune diseases such as rheumatic arthritis or myositis .
Aminoacyl tRNAsynthetase-IN-2 (Compound 14) is an aminoacyl-tRNAsynthetase (aaRS) inhibitor. Aminoacyl tRNAsynthetase-IN-2 can be used for development of a new family of antibiotics .
Aminoacyl tRNAsynthetase-IN-3 (compound 36K3) is an inhibitor of lysine tRNAsynthetase (PfLysRS) from Plasmodium falciparum (IC50=59.2 nM), which inhibits the activity of PfLysRS by occupying the ATP binding site and L-lysine binding site of PfLysRS. Aminoacyl tRNAsynthetase-IN-3 can be used in the development of antimalarial drugs .
Bersiporocin is a prolyl-tRNAsynthetase inhibitor. Bersiporocin has an IC50 of ≤100 nM for phosphoribosylpyrophosphate synthetase (PRS). Bersiporocin can be used for the research of antifibrotic .
Arg-AMS (compound 24) is a potent nanomolar inhibitor of arginyl tRNAsynthetase, which displays tightly bound inhibitory characteristics for the A-domains in non-ribosomal peptide synthetases(NRPS) enzymes .
Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNAsynthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.
mCMY416 is an orally active and blood brain barrier (BBB) permeability apicomplexan phenylalanine tRNAsynthetase inhibitor, and shows antiparasitic activity .
4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNAsynthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .
Ganfeborole hydrochloride (GSK656) is a potent antitubercular agent, acting as an inhibitor of Mycobacterium tuberculosis (Mtb) leucyl-tRNAsynthetase (LeuRS), with an IC50 of 0.2 μM.
Met-AMS TEA (compound 50), a sulfamate analogue of methionyl adenylate, is a potent Escherichia colimethionyl-tRNAsynthetase (MetRS) inhibitor (IC50 of 7 nM) .
T-3861174 is an inhibitor of prolyl-tRNAsynthetase (PRS, Aminoacyl-tRNASynthetase) without completely inhibiting its translation process. T-3861174 activates the GCN2-ATF4 pathway and induces death in multiple tumor cell lines, including SK-MEL-2. T-3861174 demonstrated significant antitumor activity in multiple xenograft models without significantly affecting body weight .
Antibacterial agent 124 (Compound 3) is a potent bacterial prolyl-tRNAsynthetase (ProRS) inhibitor with an IC50 of 0.18 μM against Staphylococcus aureus ProRS (SaProRS) .
NP-BTA is an allosteric inhibitor for glutaminyl-tRNAsynthetase (GlnRS). NP-BTA exhibits antifungal efficacy against Candida albicans, with MIC50 of 6.25 μM .
Ganfeborole (GSK656 free base) is a potent, selective and orally active inhibitor of M. tuberculosisleucyl-tRNAsynthetase, with an IC50 of 0.20 μM. Ganfeborole can be used for the research of tuberculosis .
PfThrRS-IN-1 (compound 11) is a potent inhibitor of Plasmodium falciparum threonyl tRNAsynthetase (PfThrRS), with the IC50 value of 0.1 μM. PfThrRS-IN-1 is a potent antimalaria agent .
DDD489 is a potent and selective Cryptosporidium lysyl-tRNAsynthetase (CpKRS) inhibitor with IC50 values of 0.85 uM.DDD489 shows anti-cryptosporidials activity in vitro and in vivo .
ThrRS-IN-1 (Compound 30d) is a threonyl-tRNAsynthetase (ThrRS) inhibitor with an IC50 of 1.4 µM and a Kd of 1.36 µM against Salmonella enterica ThrRS (SeThrRS). ThrRS-IN-1 simultaneously targets the tRNAThr and L-threonine binding pockets of ThrRS. ThrRS-IN-1 shows potent antibacterial activities .
Indolmycin (TAK-083), an antibiotic, is a competitive inhibitor of prokaryotic tryptophanyl-tRNAsynthetase (TrpS). Indolmycin (TAK-083) possesses both anti-viral and anti-bacterial activity .
YH16899 binds Lysyl-tRNAsynthetase (KRS), and inhibits membrane translocation of KRS. YH16899 impares the interaction of KRS with 67LR. YH16899 inhibits tumor metastasis in mouse models .
ThrRS-IN-3 (compound 36j) is a highly potent threonyl-tRNAsynthetase (ThrRS) inhibitor, with an IC50 value of 19 nM and a Kd of 34 nM for Salmonella enterica ThrRS. ThrRS-IN-3 has antibacterial activities .
Antibacterial agent 111 (Compound 3) is an antibacterial agent with MIC values of 3.90 μg/mL and 0.49 μg/mL against B. cereus and K. pneumonia, respectively. Antibacterial agent 111 firmly binds with tyrosyl-tRNAsynthetase residues .
Obafluorin is a β-Lactone Antibiotic, that can be produced by Pseudomonas fluorescens ATCC 39502. Obafluorin exhibits antibacterial activity against a range of Gram-positive and Gram-negative bacteria. Obafluorin fully inhibits E. coli threonyl-tRNAsynthetase .
Epetraborole (GSK2251052) is a leucyl-tRNAsynthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole can be used in multidrug-resistant gram-negative pathogens infection research .
Epetraborole (GSK2251052) hydrochloride is a novel leucyl-tRNAsynthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole hydrochloride can be used in multidrug-resistant gram-negative pathogens infection research .
CRS3123 (REP-3123) dihydrochloride, a fully synthetic antibacterial agent, potently inhibits methionyl-tRNAsynthetase (MetRS) of Clostridioides difficile, inhibiting Clostridioides difficile toxin production and spore formation. CRS3123 dihydrochloride is an oral agent for the research of Clostridioides difficile infection (CDI) .
Epetraborole R-mandelate is a novel leucyl-tRNAsynthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole R-mandelate can be used in multidrug-resistant gram-negative pathogens infection research .
Albomycin is an inhibitor of aminoacyl-tRNAsynthetases with Trojan-horse effect. Albomycin is delivered by iron-chelator portion into bacterial through ferrichrome-specific transporter system. Albomycin combats against a wide range of Gram-positive and Gram-negative bacteria. Albomycin also serves as an efficient iron-scavenger of producer .
Leu-AMS (compound 6), a leucine analogue, is a potent inhibitor of leucyl-tRNAsynthetase (LRS) with an IC50 of 22.34 nM, which inhibits the catalytic activity of LRS but did not affect the leucine-induced mTORC1 activation. Leu-AMS shows cytotoxicity in cancer cells and normal cells, and inhibits the growth of bacteria .
LeuRS-IN-2 (Compound 9) is a Wolbachialeucyl-tRNAsynthetase (LeuRS) inhibitor in the presence of adenosine monophosphate (AMP) with an EC50 value of 6 nM, efficiently arresting the growth of pathogenic host. LeuRS-IN-2 forms adenosine-based adducts inhibiting protein synthesis, which is promising for research of new antimicrobials with disrupting microbiota .
Efzofitimod is a splice variant of the aminoacyl-tRNAsynthetaseHARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
LysRs-IN-3 (compound 36) is an inhibitor of Plasmodium lysine tRNAsynthetase based on ASP3026 (HY-13326), which has a more than seven-fold higher inhibitory effect on the growth of Plasmodium, especially Plasmodium falciparum, than ASP3026 (HY-13326). LysRs-IN-3 can be used in the development of antimalarial drugs .
DS86760016 is a potent leucyl-tRNAsynthetase (LeuRS) inhibitor with activity against multidrug-resistant (MDR) Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. DS86760016 inhibits LeuRS enzymes from Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, with IC50s of 0.38, 0.62, and 0.16 μM, respectively .
CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNAsynthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .
Antibacterial agent 227 (Compd 29) is a SerRS (Seryl-tRNAsynthetase) inhibitor. Antibacterial agent 227 has a significant inhibitory effect on the growth of planktonic and biofilm culture of Staphylococcus aureus 25923 with MIC (minimum inhibitory concentration) value of 32 µg/ml. Antibacterial agent 227 can be proposed as effective antiseptic toward multidrug-resistant biofilm-forming S. aureus isolates .
BC-1293 is an inhibitor for E3 ligase subunit FBXO24. BC-1293 disrupts the interaction between FBXO24 and aspartyl-tRNAsynthetase (DARS2) and increases the level of DARS2. BC-1293 increases levels of IL-1β, IL-9, MIP-2, and TNF α, and exhibits immunostimulatory activity in mice .
Antileishmanial agent-27 (compound 7j) is a benzothiazolo-coumarin derivative. Antileishmanial agent-27 is a competitive inhibitor of arginyl-tRNAsynthetases (ArgRSs). Antileishmanial agent-27 shows selectivity toward ArgRS of Leishmania donovani (LdArgRS) than its human counterpart (HsArgRS), with IC50 values of 1.2 and 19 μM, respectively. Antileishmanial agent-27 possesses high pharmacokinetic properties .
LeuRS-IN-1 is a potent, orally active M. tuberculosis leucyl-tRNAsynthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 has IC50 and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively . LeuRS-IN-1 inhibits human cytoplasmic LeuRS (IC50=38.8 μM), and HepG2 protein synthesis (EC50=19.6 μM) .
LeuRS-IN-1 hydrochloride is a potent, orally active M. tuberculosis leucyl-tRNAsynthetase (M.tb LeuRS) inhibitor. LeuRS-IN-1 hydrochloride has IC50 and Kd values of 0.06 μM, 0.075 μM for M.tb LeuRS, respectively . LeuRS-IN-1 hydrochloride inhibits human cytoplasmic LeuRS (IC50=38.8 μM), and HepG2 protein synthesis (EC50=19.6 μM) .
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
L-Azidonorleucine hydrochloride, an unnatural amino acid, is A Methionine surrogate. L-Azidonorleucine hydrochloride can be used to label mammalian cell proteins and identify a diverse set of methionyl-tRNAsynthetase (MetRS) mutants . L-Azidonorleucine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Antileishmanial agent-19 (Compound F27) is an antileishmanial agent, with a IC50 of 3.39 μM for L. donovani promastigotes. Antileishmanial agent-19 inhibits Leishmaniaprolyl-tRNAsynthetase. Antileishmanial agent-19 inhibits host PI3K/Akt/CREB axis-mediated IL-10 secretion. Antileishmanial agent-19 induces autophagy-mediated apoptosis in L. donovani promastigotes. Antileishmanial agent-19 reduces parasite burden in L.d-infected animals .
UAA crosslinker 1 hydrochloride is an amber codon used for non-canonical amino acids (ncAAs) incorporation. The ncAAs can be incorporated into proteins in vivo by making use of the promiscuous activity of certain wildtype and engineered aminoacyl-tRNAsynthetases . UAA crosslinker 1 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
UAA crosslinker 1 hydrochloride is an amber codon used for non-canonical amino acids (ncAAs) incorporation. The ncAAs can be incorporated into proteins in vivo by making use of the promiscuous activity of certain wildtype and engineered aminoacyl-tRNAsynthetases . UAA crosslinker 1 (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Borrelidin (Treponemycin) is a bacterial and eukaryal threonyl-tRNAsynthetase inhibitor which is a nitrile-containing macrolide antibiotic isolated from Streptomyces rochei . Borrelidin is an inhibitor of Cdc28/Cln2 of the budding yeast, with an IC50 of 24 μM . Borrelidin is a potent angiogenesis inhibitor, with an IC50 of 0.8 nM. Borrelidin induces apoptosis in the tube-forming cells . Borrelidin has strong antimalarial activities, with IC50s of 1.9 nM and 1.8 nM against K1 and FCR3 strains of Plasmodium falciparum, respectively .
Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Halofuginone (hydrochloride) (Standard) is the analytical standard of Halofuginone (hydrochloride). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects [4] .
Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNAsynthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
N-Formyl-L-histidine shows binding affinity to histidyl-tRNAsynthetase with a Ki value of 4.6 μM. N-Formyl-L-histidine shows a competitive inhibition against L-histidine ammonia-lyase, inhibits urocanic acid formation from L-histidine with a Ki value of 4.26 mM .
Efzofitimod is a splice variant of the aminoacyl-tRNAsynthetaseHARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Borrelidin (Treponemycin) is a bacterial and eukaryal threonyl-tRNAsynthetase inhibitor which is a nitrile-containing macrolide antibiotic isolated from Streptomyces rochei . Borrelidin is an inhibitor of Cdc28/Cln2 of the budding yeast, with an IC50 of 24 μM . Borrelidin is a potent angiogenesis inhibitor, with an IC50 of 0.8 nM. Borrelidin induces apoptosis in the tube-forming cells . Borrelidin has strong antimalarial activities, with IC50s of 1.9 nM and 1.8 nM against K1 and FCR3 strains of Plasmodium falciparum, respectively .
Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNAsynthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
The KARS protein promotes attachment of amino acids to its cognate tRNA through a two-step reaction, inducing immune responses through monocyte/macrophage activation. In microbial infections, it interacts with the HIV-1 GAG protein to enable selective tRNA(3)(Lys) packaging to initiate reverse transcription. KARS Protein, Human (HEK293, His) is the recombinant human-derived KARS protein, expressed by HEK293 , with C-6*His labeled tag.
The Alanyl-tRNA synthetase protein facilitates a two-step process, activating alanine with ATP to form Ala-AMP and transferring it to the acceptor end of tRNA(Ala). Additionally, it corrects incorrectly charged tRNA(Ala) through its editing domain. Alanyl-tRNA synthetase Protein, Human (sf9, His) is the recombinant human-derived Alanyl-tRNA synthetase protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of Alanyl-tRNA synthetase Protein, Human (sf9, His) is 968 a.a., with molecular weight of ~109.2 kDa.
AARS1, a pivotal enzyme in protein synthesis, plays a crucial role in the attachment of alanine to tRNA(Ala) through a two-step process. Initially, alanine undergoes activation by ATP to form Ala-AMP, and subsequently, it is transferred to the acceptor end of tRNA(Ala). Beyond its primary aminoacylation function, AARS1 boasts an editing domain that enables the correction of incorrectly charged tRNA(Ala), underscoring its role in maintaining the fidelity of the translation process. This dual functionality highlights AARS1's significance in ensuring the accuracy and integrity of the protein synthesis machinery. AARS1 Protein, Mouse (sf9, His) is the recombinant mouse-derived AARS1 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of AARS1 Protein, Mouse (sf9, His) is 968 a.a., with molecular weight of ~108 kDa.
AARSD1 Protein actively functions in trans to edit the amino acid moiety from incorrectly charged tRNA(Ala). AARSD1 Protein, Human (His) is the recombinant human-derived AARSD1 protein, expressed by E. coli , with N-His labeled tag. The total length of AARSD1 Protein, Human (His) is 350 a.a., with molecular weight of ~40 KDa.
WARS includes isomer 1, isomer 2, T1-TrpRS and T2-TrpRS, and has aminoacylation activity, except T2-TrpRS. Unlike isoform 1, isoform 2, T1-TrpRS and T2-TrpRS, exhibit vasostatic activity. WARS Protein, Human (His) is the recombinant human-derived WARS protein, expressed by E. coli , with N-6*His labeled tag. The total length of WARS Protein, Human (His) is 471 a.a., with molecular weight of ~60.0 kDa.
L-Azidonorleucine hydrochloride, an unnatural amino acid, is A Methionine surrogate. L-Azidonorleucine hydrochloride can be used to label mammalian cell proteins and identify a diverse set of methionyl-tRNAsynthetase (MetRS) mutants . L-Azidonorleucine (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
UAA crosslinker 1 hydrochloride is an amber codon used for non-canonical amino acids (ncAAs) incorporation. The ncAAs can be incorporated into proteins in vivo by making use of the promiscuous activity of certain wildtype and engineered aminoacyl-tRNAsynthetases . UAA crosslinker 1 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
UAA crosslinker 1 hydrochloride is an amber codon used for non-canonical amino acids (ncAAs) incorporation. The ncAAs can be incorporated into proteins in vivo by making use of the promiscuous activity of certain wildtype and engineered aminoacyl-tRNAsynthetases . UAA crosslinker 1 (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Inquiry Online
Your information is safe with us. * Required Fields.
